NAD+

At a glance

---

What is NAD+?

First, the important distinction: NAD+ is not a peptide. It has no amino acids, no peptide bonds, and no sequence. It is a dinucleotide coenzyme — two nucleotides joined by a pyrophosphate linkage, one containing adenine and the other nicotinamide. We include it here because peptide clinics and longevity platforms routinely sell NAD+ therapy alongside peptide therapies, and consumers encounter it in the same space.^[1]

NAD+ stands for nicotinamide adenine dinucleotide, and the "+" indicates its oxidized form — the form ready to accept electrons. It was first identified in 1906 by Arthur Harden and William John Young, who discovered it as a heat-stable cofactor essential for yeast fermentation. They called it "cozymase." The Nobel Prize in Chemistry was awarded for this work in 1929.^[12]

NAD+ is not something exotic or novel. It is present in every cell of every living organism — from bacteria to humans. It is as fundamental to life as ATP. Your body synthesizes NAD+ continuously through multiple pathways, and it participates in hundreds of enzymatic reactions every second.

The therapeutic idea behind NAD+ supplementation is straightforward: NAD+ levels decline with age — by some estimates, up to 50% by middle age — and this decline is associated with many age-related problems. Restoring NAD+ to "youthful" levels might, in theory, improve cellular function. Whether that theory translates to meaningful clinical benefits is the central question.

---

How it works

In plain terms, NAD+ serves as a rechargeable battery in your cells. It shuttles electrons between chemical reactions, enabling your cells to convert food into energy, repair damaged DNA, and regulate gene expression. When NAD+ accepts electrons, it becomes NADH (the "charged" form). NADH then donates those electrons to produce ATP — the energy currency of the cell.^[1]

But NAD+ does far more than energy metabolism. It is also a critical signaling molecule consumed by three major classes of enzymes:

• Sirtuins — NAD+-dependent proteins that regulate gene expression, DNA repair, and mitochondrial function. Sirtuin activity depends directly on NAD+ availability.
• PARPs — DNA damage repair enzymes that consume NAD+ as they work. PARP1 alone may consume 80% of cellular NAD+ during intensive DNA repair.
• CD38 — An enzyme that increases with age and is now considered the primary driver of age-related NAD+ decline.

Why NAD+ declines with age (detailed)

The age-related decline in NAD+ is driven by three converging factors:^[3]

1. Increased CD38 expression: CD38 is a membrane-bound enzyme that degrades NAD+. Its levels rise substantially with age, driven partly by chronic low-grade inflammation ("inflammaging"). CD38 also degrades NMN (a NAD+ precursor), creating a double problem.

2. Increased PARP activation: As DNA damage accumulates with age, PARP enzymes consume more NAD+ for repair. This creates a "NAD+ drain" — the more damage your cells accumulate, the more NAD+ they burn through trying to fix it.

3. Decreased NAMPT expression: NAMPT is the rate-limiting enzyme in the NAD+ salvage pathway (the main pathway for recycling NAD+). Its expression decreases with age, reducing the body's ability to regenerate NAD+.

The result: supply drops while demand increases. This is the core biological rationale for NAD+ supplementation — and it is scientifically sound. The question is whether raising NAD+ levels from the outside produces the same benefits as the youthful levels your body maintained naturally.

How different NAD+-boosting strategies work

Not all NAD+ delivery methods are equal, and the evidence differs substantially:

Approach	How it works	Evidence
IV NAD+	Direct infusion into bloodstream	Most expensive, most marketed, least evidence. Whether IV NAD+ actually enters cells in meaningful amounts (vs. being broken down extracellularly by CD38) is debated.
Subcutaneous NAD+ injection	Slower absorption than IV	Same bioavailability questions. Growing telehealth market.
NR (Nicotinamide Riboside)	Oral precursor; enters cells and is converted to NMN, then NAD+	Most human trial data of any NAD+ strategy. Proven to raise blood NAD+ levels.
NMN (Nicotinamide Mononucleotide)	Oral precursor; one step closer to NAD+ in the salvage pathway	Growing human trial data. Raises blood NAD+.
Niacin (Nicotinic acid)	Oldest NAD+ precursor; Preiss-Handler pathway	Proven to raise NAD+. Causes flushing. FDA-approved for dyslipidemia.

The irony: the cheapest delivery methods (oral NR and NMN) have more clinical trial evidence than the most expensive one (IV NAD+).

---

What the research says

The basic science of NAD+ is robust and compelling. What keeps not arriving is the clinical benefit. In 2026 a trial doubled blood NAD+ in older adults with mild cognitive impairment and cognition did not move; a meta-analysis of 15 NMN trials found the supplement well tolerated and metabolically inert. Meanwhile the most expensive form of NAD+ therapy still has zero controlled trials.

Research timeline

NAD+ has one of the longest research histories of any molecule in the longevity space — over a century of scientific study:

Human clinical trials

The human evidence picture for NAD+ is more nuanced than for most compounds on this site, because the evidence differs dramatically depending on which form you're asking about. Here is a critical distinction that most NAD+ marketing materials blur:

Notice what is absent from this list: any controlled trial of IV NAD+ for any indication. The most expensive, most marketed form of NAD+ therapy has the weakest evidence base. This is not an oversight — the data simply does not exist yet.

What 2026 added — and why it matters

Two results published in 2026 sharpen the central question on this page, and both point the same direction.

The first is the cleanest test yet of the entire NAD+ hypothesis. In a phase-II randomized, double-blind, placebo-controlled pilot, older adults with amnestic mild cognitive impairment took nicotinamide riboside for 12 weeks. Blood NAD+ doubled. Cognitive function, the primary outcome, did not improve. Neither did total cerebral blood flow or blood pressure.^[14]

That is the whole argument in miniature. The supplement did exactly what it is supposed to do at the biochemical level — and nothing measurable happened at the level anyone actually cares about. It is worth adding that the trial was led by an investigator with a track record of positive NR findings, including the well-known 2018 blood-pressure work. This is not a null result from a skeptic.

The second is a meta-analysis of 15 NMN trials, covering doses from 250 to 2,000 mg/day over periods from two weeks to six months. Its two conclusions sit together neatly: NMN did not increase overall, serious, withdrawal-related or system-specific adverse events, and did not elevate liver enzymes — and it also produced no significant effect on body weight, BMI, fasting glucose, HbA1c, lipid profiles or systolic blood pressure. The only signal was a small decrease in diastolic blood pressure. The authors' own summary: broad metabolic benefits were not evident.^[15]

Basic science

The basic science of NAD+ is genuinely impressive — this is not a fringe molecule with speculative mechanisms. NAD+ has been studied for over a century, and its biochemistry is textbook-level established.^[1]

Key established findings

• Metabolic role: NAD+ participates in over 500 enzymatic reactions. It is essential for glycolysis, the TCA cycle, and oxidative phosphorylation. Without NAD+, cellular energy production stops.
• Age-related decline: Consistently demonstrated in human studies across multiple tissues — blood, skin, liver, muscle, and brain. The decline is real and well-documented.^[3]
• Sirtuin regulation: NAD+ is the required cofactor for all seven human sirtuins (SIRT1-7). Sirtuins regulate gene expression, DNA repair, mitochondrial biogenesis, inflammation, and circadian rhythm.
• DNA repair: PARPs consume NAD+ to repair DNA damage. Maintaining NAD+ pools supports the DNA damage response.
• Alzheimer's research: A 2025 study in Science Advances showed NAD+ augmentation corrected alternative splicing events relevant to Alzheimer's disease via the EVA1C protein in mouse models.^[10]
• Blood levels can be raised: Multiple human RCTs confirm that oral NR and NMN reliably increase blood NAD+ and related metabolites.

---

What the evidence shows

NAD+ marketing tends to blur the line between established biochemistry and clinical evidence. Here's what the published research actually supports for the most common claims:

---

Safety & side effects

Oral precursors (NR and NMN)

The safety profile for oral NR and NMN is the best-characterized of any NAD+-boosting strategy:^[9]

• NMN at 100-1,250 mg/day has shown no serious adverse events in trials up to 12 weeks
• NR at 300-2,000 mg/day has been well tolerated across multiple RCTs
• Common side effects: mild GI discomfort, headaches at higher doses, niacin-like flushing
• A 2024 systematic review concluded that NAD+ precursor supplementation is "safe" based on current data, but long-term studies in large cohorts are lacking

IV NAD+

IV NAD+ has no controlled safety trials but extensive anecdotal reporting. Commonly reported effects during infusion include:

• Nausea (very common, dose and rate-dependent)
• Chest tightness or pressure
• Flushing and warmth
• Headache
• Abdominal cramping
• Muscle cramping
• Light-headedness and dizziness
• Anxiety and a "sense of impending doom"

Most of these effects are managed by slowing the infusion rate, which is why IV NAD+ sessions typically run 2-4 hours.

The compounding quality problem

Theoretical risks

Cancer concern and drug interactions

Cancer concern: NAD+ fuels cellular metabolism broadly — including cancer cells. Rapidly increasing NAD+ could theoretically support tumor growth or help cancer cells resist metabolic stress. Preclinical evidence is mixed; some studies show NAD+ boosting is protective, others suggest it could fuel existing cancers. No human evidence of harm exists, but the theoretical concern is legitimate and under-discussed in marketing materials.

PARP inhibitor interaction: Cancer patients on PARP inhibitors (olaparib, niraparib, etc.) should not take NAD+ supplements. NAD+ could counteract the drug's mechanism — PARP inhibitors work by exploiting cancer cells' reliance on PARP-mediated repair, and adding NAD+ could undermine this therapeutic strategy.

Other theoretical contraindications:

• Active malignancy (theoretical concern about fueling cancer metabolism)
• Cardiovascular disease / hypotension for IV (risk of fluid overload and hemodynamic effects)
• Pregnancy / breastfeeding (no safety data)
• Patients on MAO inhibitors
• Immunosuppressants (unknown interactions with NAD+-dependent immune pathways)

---

How people use it

NAD+ therapy spans three distinct market tiers — and the relationship between price and evidence is inverted:

Administration routes

• IV infusion ($250-$1,500 per session): The premium tier. Sessions run 2-4 hours with slow infusion to manage side effects. The most expensive option and the one with the least clinical evidence.
• Subcutaneous injection ($100-$400/month): Growing telehealth market. Same bioavailability questions as IV. Injection site reactions are common.
• Oral NR supplements ($40-$60/month): The most studied delivery method. ChromaDex's Tru Niagen has NDI notification and GRAS status.
• Oral NMN supplements ($30-$80/month): Growing trial data. Widely available over the counter.

The price-evidence inversion

This is worth stating plainly: the cheapest options (oral NR and NMN supplements at $30-$60/month) have the most clinical trial data. The most expensive option (IV NAD+ at $250-$1,500 per session) has essentially none. The marketing claim that "you need IV NAD+ because oral precursors don't work" is not supported by any published clinical comparison.

Oral NR and NMN have been shown in multiple RCTs to raise blood NAD+ levels. IV NAD+ raises blood levels too — but whether IV NAD+ actually enters cells in meaningful amounts (rather than being degraded extracellularly by CD38) is an open scientific question.

Common stacking context

In clinic and community practice, NAD+ is often combined with:

• Resveratrol — Sirtuin activator; the David Sinclair protocol combines it with NMN. Limited human evidence for the combination.
• Trimethylglycine (TMG) — NAD+ metabolism consumes methyl groups; TMG provides methyl donors. Theoretical rationale, no clinical trials.
• Glutathione — Often added to IV NAD+ infusions. No evidence for synergy.
• Quercetin / Fisetin — Potential CD38 inhibitors (reduce NAD+ consumption). Preclinical evidence only.

All combination protocols are community-derived or practitioner-recommended and have not been studied in controlled settings.

---

Legal & regulatory status

As of August 2026:

FDA status

NAD+ is not FDA-approved as a drug for any indication. Unlike BPC-157 and several other peptides, NAD+ was not placed on the FDA's Category 2 restricted list. It remains eligible for compounding under 503A/503B pathways with a valid prescription.

However, the FDA has expressed concerns about compounding quality. A compounded NAD+ injection product was recalled in July 2025 and the recall classified Class I in October 2025 for elevated endotoxin — the most serious classification.^[13]

Supplement status

• NR (as Niagen, ChromaDex) has New Dietary Ingredient (NDI) notification and GRAS (Generally Recognized as Safe) status. The most regulatory-validated NAD+ precursor.
• NMN is widely sold as a dietary supplement, and its status has been genuinely contested — this is the single most-asked regulatory question about NMN, and the page previously skipped over it.

The NMN exclusion fight

In November 2022, FDA concluded that beta-nicotinamide mononucleotide (NMN) was excluded from the dietary supplement definition. The reasoning turned on the drug-preclusion clause of the FD&C Act: broadly, if a substance was authorized for investigation as a new drug before it was marketed as a supplement, it cannot then be sold as a supplement. That determination put a widely sold ingredient in legal limbo for two years, even as it stayed on shelves.

A trade association filed a citizen petition and subsequently sued. According to the petitioner and to trade press coverage, FDA reversed course in letters dated September 29, 2025, concluding that NMN does meet the dietary supplement definition — reportedly on a "race to market" analysis, with evidence that NMN was marketed as a supplement in the US as early as 2017. Further NDI-status letters to ingredient companies were reported in December 2025.^[16]

Either way, NMN supplements have remained widely available throughout, and the practical situation for a consumer has not changed.

WADA / USADA status

NAD+, NMN, and NR are not prohibited by WADA. They are not on the Prohibited List. Athletes should use third-party tested products (NSF for Sport, Informed Choice) to avoid contamination with banned substances.

---

How IV NAD+ compares to oral precursors

The most important comparison for consumers isn't NAD+ vs. another compound — it's the different delivery methods for NAD+ itself:

The contrast is worth reflecting on. The supplement form that anyone can buy for $40/month has been studied in multiple randomized controlled trials and has a reasonable safety profile. The clinic form that costs $250-$1,500 per session and requires 2-4 hours in a chair has zero controlled trials. The evidence doesn't support the premium pricing — at least not yet.

This doesn't mean IV NAD+ cannot work. It means the data to justify the cost and inconvenience does not currently exist.

---

References

1. [1]

   Covarrubias AJ, Perrone R, Grozio A, Verdin E. “NAD+ metabolism and its roles in cellular processes during ageing.” Nat Rev Mol Cell Biol. 2021. 22(2):119–141 DOI PubMedReview

   Comprehensive review of NAD+ biology and its role in aging. Foundational reference for understanding NAD+ decline.

2. [2]

   Rajman L, Chwalek K, Sinclair DA. “Therapeutic potential of NAD-boosting molecules: the in vivo evidence.” Cell Metab. 2018. 27(3):529–547 DOI PubMedReview

   Major review of in vivo evidence for NAD+ boosting across organ systems.

3. [3]

   Camacho-Pereira J, Tarragó MG, Chini CCS, et al.. “CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism.” Cell Metab. 2016. 23(6):1127–1139 DOI PubMedAnimal study

   Landmark paper establishing CD38 as a primary driver of age-related NAD+ decline.

4. [4]

   Morifuji M, et al.. “Ingestion of β-nicotinamide mononucleotide increased blood NAD levels, maintained walking speed, and improved sleep quality in older adults.” Geroscience. 2024. 46(5):4671–4688 DOI PubMedRCT

   Double-blind RCT with 60 older adults (65–75 years). 250 mg/day NMN for 12 weeks. Industry-sponsored (Meiji Holdings).

5. [5]

   Wu CY, Reynolds WC, Abril I, McManus AJ, Brenner C, et al.. “Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial.” eClinicalMedicine (Lancet). 2025. 89:103633 DOI PubMedRCT

   Double-blind, placebo-controlled (n=58). 2,000 mg/day NR raised blood NAD+ 2.6–3.1-fold but showed no significant between-group improvement in cognition or symptoms.

6. [6]

   Wang JP, Wang L, Wang T, Zhang YD, Zhou AJ, et al.. “Effects of nicotinamide mononucleotide supplementation on muscle and liver functions among the middle-aged and elderly: a systematic review and meta-analysis of randomized controlled trials.” Curr Pharm Biotechnol. 2025. 26(13):2141-2152 DOI PubMedSystematic review

   Meta-analysis of 9 RCTs with 412 participants. Positive effects on muscle mass and gait speed.

7. [7]

   Zhang J, Poon ET, Wong SH. “Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials.” Crit Rev Food Sci Nutr. 2025. 65(22):4382-4400 DOI PubMedSystematic review

   12 studies, 513 participants. NMN raised blood NAD+ significantly, but most metabolic endpoints showed no significant differences vs. control.

8. [8]

   Orr ME, Kotkowski E, Ramirez P, Bair-Kelps D, Liu Q, et al.. “A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.” Geroscience. 2024. 46(1):665-682 DOI PubMedPilot study

   Pilot study with 20 subjects. Dose escalation to 1 g/day NR over 10 weeks. Safety and tolerability focus.

9. [9]

   Gindri IM, Ferrari G, Pinto LPS, Bicca J, Dos Santos IK, et al.. “Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review.” Am J Physiol Endocrinol Metab. 2024. 326(4):E417-E427 DOI PubMedSystematic review

   10 trials, 489 participants. Assessed only oral NADH/NAD+ supplementation (not injectable or IV NAD+); concluded oral supplementation is safe with a low incidence of side effects and associated with improved quality of life.

10. [10]

    Ai R, Mao L, Jin X, Campos-Marques C, Zhang SQ, et al.. “NAD+ reverses Alzheimer’s neurological deficits via regulating differential alternative RNA splicing of EVA1C.” Science Advances. 2025. 11(45):eady9811 DOI PubMedAnimal study

    Preclinical study demonstrating NAD+ augmentation corrects splicing events via EVA1C in Alzheimer’s models. Clinical trials ongoing.

11. [11]

    Radenkovic D, Reason, Verdin E. “Clinical evidence for targeting NAD therapeutically.” Pharmaceuticals. 2020. 13(9):247 DOI PubMedReview
12. [12]

    Harden A, Young WJ. “The alcoholic ferment of yeast-juice.” Proc R Soc Lond B. 1906. 78:369–375

    The foundational paper describing the discovery of NAD+ (then called 'cozymase'). Nobel Prize in Chemistry awarded to Harden and von Euler-Chelpin in 1929.

13. [13]

    U.S. Food and Drug Administration. “Class I Recall — NAD+ for Injection (GenoGenix LLC, elevated endotoxin levels).” 2025. Link

    Voluntary recall initiated July 30, 2025; classified Class I (FDA's most serious level) on October 21, 2025. Lot GG121624-023. An unopened vial tested at 3,360 EU/mL bacterial endotoxin; three patients reported hypotension, uncontrollable shaking, shivers and body aches. Recall specifics are from pharmacy trade press rather than FDA's enforcement report.

14. [14]

    Martens CR, Decker KP, DeConne TM, Sanjana F, Horvat F, et al.. “A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with mild cognitive impairment.” Alzheimers Dement. 2026. 22(7):e71605 DOI PubMedRCT

    Double-blind, placebo-controlled, n=42 (NR 22, placebo 20), 12 weeks. Blood NAD+ doubled; cognition (the primary outcome), total cerebral blood flow and blood pressure were unchanged. Led by an investigator known for earlier positive NR work, which strengthens rather than weakens the null result.

15. [15]

    Yang W, Huang J, Tang Z, Chen C, Sun Y. “Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation: a systematic review and meta-analysis.” Nutrients. 2026. 18(14):2251 DOI PubMedSystematic review

    15 trials (10 contributing to safety analyses), NMN 250–2,000 mg/day for 14 days to 24 weeks. Favorable short-term tolerability; no significant effect on body weight, BMI, fasting glucose, HbA1c, lipids or systolic blood pressure. Published in Nutrients, a lower-tier journal — weigh accordingly, though the direction of the finding is consistent with earlier meta-analyses.

16. [16]

    Natural Products Association. “FDA reinstates NMN as a lawful dietary supplement ingredient following citizen petition and litigation.” 2025. LinkReview

    Account by the petitioning trade association, corroborated by trade press, reporting FDA letters dated September 29, 2025 concluding that NMN does meet the dietary supplement definition — reversing FDA's November 2022 drug-preclusion determination. We were not able to obtain FDA's letters or the docket directly, so this is reported rather than independently confirmed.

17. [17]

    Prokopidis K, Moriarty F, Bahat G, McLean J, Church DD, Patel HP. “The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis.” J Cachexia Sarcopenia Muscle. 2025. 16(3):e13799 DOI PubMedSystematic review

    Most recent meta-analysis. Found current evidence does not conclusively support NMN/NR for preserving muscle mass and function in adults over 60.

---